TNF and arthritic joint disease: Salubrinal, a selective eIF2α dephosphorylation inhibitor, has been shown to reduce the release of pro-inflammatory cytokines (IL-1β, IL-2, IL-13, and TNF) and the expression of the Dusp2 gene in a mouse model of CIA, alleviating arthritis progression (62, 63).